



PRIOR AUTHORIZATION REQUEST

Direct Renin Inhibitors

Patient Information:

Name:	
Member ID:	
Address:	
City, State, Zip:	
Date of Birth:	

Prescriber Information:

Name:	
NPI:	
Phone Number:	
Fax Number:	
Address:	
City, State, Zip:	

Requested Medication

Rx Name:	
Rx Strength:	
Rx Quantity:	
Rx Frequency:	
Rx Route of Administration:	
Diagnosis and ICD Code:	

Your patient's prescription benefit requires that we review certain requests for coverage with the prescriber. You have prescribed a medication for your patient that requires Prior Authorization before benefit coverage or coverage of additional quantities can be provided. Please complete the following questions then fax this form to the toll-free number listed below. Upon receipt of the completed form, prescription benefit coverage will be determined based on the plan's rules.

SECTION A: Please note that supporting clinical documentation is required for **ALL** PA requests.

- | | | | |
|---|---|-----|----|
| 1 | What is the diagnosis or indication?

<input type="checkbox"/> Hypertension (HTN) (If checked, go to 2)

<input type="checkbox"/> Other (If checked, no further questions) | | |
| 2 | Is the patient 18 years of age or older?
[If no, no further questions.] | Yes | No |
| 3 | Has the patient experienced an inadequate response or inability to tolerate a trial of a formulary angiotensin receptor blocker (ARB) and angiotensin-converting enzyme (ACE) inhibitors? | Yes | No |

If you have any
questions, call:
1-888-258-8250

PRIOR AUTHORIZATION REQUEST

[NOTE: The formulary angiotensin receptor blockers (ARBs) include: losartan, losartan/HCTZ, irbesartan, valsartan/HCTZ, candesartan, candesartan/HCTZ, valsartan, valsartan/HCTZ, amlodipine/valsartan; amlodipine/valsartan/HCTZ. The formulary angiotensin-converting enzyme (ACE) inhibitors include: lisinopril, lisinopril/HCTZ, benazepril, benazepril/HCTZ, captopril, captopril/HCTZ, enalapril, enalapril/HCTZ, fosinopril, fosinopril/HCTZ, quinapril, quinapril/HCTZ, ramipril, perindopril, amlodipine/benazepril, moexipril, moexipril/HCTZ, trandolapril.]
[If no, no further questions.]

- | | | | |
|---|--|-----|----|
| 4 | Has the patient experienced an inadequate response or inability to tolerate AT LEAST ONE other formulary antihypertensive agent from a different therapeutic class: thiazide-type diuretic, calcium channel blocker, and beta-blocker?
[NOTE: Formulary thiazide-type diuretics include: chlorothiazide, Diuril, HCTZ, indapamide, methyclothiazide, metolazone. Formulary calcium channel blockers include: diltiazem, diltiazem ER, nifedipine, nifedipine ER, verapamil, verapamil ER, amlodipine, isradipine, nicardipine, nimodipine, felodipine ER, nisoldipine ER, Cartia XT, Taztia XT, Nifedical XL, Afeditab CR, Nifediac CC, Dilt-SR. Formulary beta-blockers include: atenolol, atenolol/chlorthalidone, bisoprolol, bisoprolol/HCTZ, carvedilol, metoprolol tartrate, metoprolol succinate, metoprolol/HCTZ, nadolol, nadolol/bendroflumethiazide, pindolol, propranolol, propranolol ER, propranolol/HCTZ, sotalol, sotalol (AF), timolol, acebutolol, betaxolol, labetalol.]
[If no, no further questions.] | Yes | No |
| | | | |
| 5 | Is this medication being used in combination with an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB)? | Yes | No |

Please document the diagnoses, symptoms, and/or any other information important to this review:

SECTION B: Physician Signature

PHYSICIAN SIGNATURE

DATE

FAX COMPLETED FORM TO: 1-833-896-0656

Disclaimer: An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior authorization as per Plan policy and procedures.

**If you have any
questions, call:
1-888-258-8250**



PRIOR AUTHORIZATION REQUEST

Confidentiality: The information contained in this transmission is confidential and may be protected under the Health Insurance Portability and Accountability Act of 1996. If you are not the intended recipient any use, distribution, or copying is strictly prohibited. If you have received this facsimile in error, please notify us immediately and destroy this document.

If you have any
questions, call:
1-888-258-8250